Charles River hunts for deals to serve strategic discovery clients
Charles River wants to buy drug discovery assets to meet interest in strategic outsourcing of non-regulated efficacy testing.
Charles River wants to buy drug discovery assets to meet interest in strategic outsourcing of non-regulated efficacy testing.
LabCorp has finally been cleared to buy DNA testing services firm Orchid Cellmark after the US Federal Trade Commission (FTC) OKed the deal, albeit, with some conditions.
Six Asian CROs have set up a regional network and claim their local knowledge will make conducting clinical trials in the region more straightforward.
AMPAC posted a fourth quarter loss as process improvement difficulties offset rising demand for CNS and oncology ingredients.
AIT Bioscience says its new alliance with Perfinity Biosciences will provide protein analysis in 10 minutes, rather than the 48 hours that is standard across the industry.
Seppic has seen a boom in demand for its new natural origin coating agents for pharmaceuticals, which can speed up production time by 50 per cent at lab stage.
Researchers have developed a Trojan-horse-style delivery system that transports steroids to the retina for the treatment of age-related macular degeneration and retinitis pigmentosa.